View in EDS

Plasminogen Activator Inhibitor‐1 in the Pathophysiology of Late Life Depression.

Saved in:
Bibliographic Details
Title: Plasminogen Activator Inhibitor‐1 in the Pathophysiology of Late Life Depression.
Authors: Métivier, L., Vivien, D., Goy, R., Agin, V., Bui, E., Benbrika, S.
Source: International Journal of Geriatric Psychiatry. Nov2024, Vol. 39 Issue 11, p1-14. 14p.
Subjects: Mental depression risk factors, Adipokines, Health status indicators, Cellular aging, Apoptosis, Sedentary lifestyles, Geriatric psychiatry, Insulin, Tissue plasminogen activator, Blood coagulation factors, Antidepressants, Gene expression, Protease inhibitors, Aging, Fibrinolysis, Psychological stress, Cytokines, Inflammation, Cushing's syndrome, Mental depression, Drug resistance, Biomarkers, Interleukins, Old age
Abstract: Introduction: Late life depression (LLD) is characterized by specific clinical features including a high frequency of vascular form and frequent antidepressant treatment resistance. The expression and functions of the serine protease inhibitor, Plasminogen Activator Inhibitor‐1 (PAI‐1) is known to be altered by aging, vascular damage, insulin levels associated with a sedentary lifestyle, chronic stress leading to hypercortisolemia, and inflammatory changes linked to stress responses. These phenomena would be implicated in LLD like vascular depression. This article thus aims to review the existing literature regarding the association between LLD and plasmatic levels of PAI‐1, a marker of hypofibrinolysis. We hypothesize that increased age would be associated with changes in PAI‐1 plasma level and function which influence LLD pathogenesis and its treatment. Results: Although a large number of studies on PAI‐1 changes in the elderly exist, studies about its implications in LLD are sparse. Despite heterogeneous findings regarding the direction of variation in plasmatic PAI‐1 levels among elderly participants with LLD, all studies demonstrated an association between PAI‐1 levels and current or remitted depressive symptoms. Moreover, disruptions in the concentrations of other biological markers influencing PAI‐1 expression, such as cytokines or adipokines, were also observed, notably an increase in the levels of interleukins 6 and 8. Discussion: LLD genesis appears to be influenced by PAI‐1 regulatory loops which are implicated in senescence or cell death. The resistance to antidepressant treatment appears to be linked to distinct biological profiles involving inflammatory and fibrinolytic factors. Taken together these data suggest that PAI‐1 pathway may be a promising target of treatment development efforts for LLD, and depression in general. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Geriatric Psychiatry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Introduction: Late life depression (LLD) is characterized by specific clinical features including a high frequency of vascular form and frequent antidepressant treatment resistance. The expression and functions of the serine protease inhibitor, Plasminogen Activator Inhibitor‐1 (PAI‐1) is known to be altered by aging, vascular damage, insulin levels associated with a sedentary lifestyle, chronic stress leading to hypercortisolemia, and inflammatory changes linked to stress responses. These phenomena would be implicated in LLD like vascular depression. This article thus aims to review the existing literature regarding the association between LLD and plasmatic levels of PAI‐1, a marker of hypofibrinolysis. We hypothesize that increased age would be associated with changes in PAI‐1 plasma level and function which influence LLD pathogenesis and its treatment. Results: Although a large number of studies on PAI‐1 changes in the elderly exist, studies about its implications in LLD are sparse. Despite heterogeneous findings regarding the direction of variation in plasmatic PAI‐1 levels among elderly participants with LLD, all studies demonstrated an association between PAI‐1 levels and current or remitted depressive symptoms. Moreover, disruptions in the concentrations of other biological markers influencing PAI‐1 expression, such as cytokines or adipokines, were also observed, notably an increase in the levels of interleukins 6 and 8. Discussion: LLD genesis appears to be influenced by PAI‐1 regulatory loops which are implicated in senescence or cell death. The resistance to antidepressant treatment appears to be linked to distinct biological profiles involving inflammatory and fibrinolytic factors. Taken together these data suggest that PAI‐1 pathway may be a promising target of treatment development efforts for LLD, and depression in general. [ABSTRACT FROM AUTHOR]
ISSN:08856230
DOI:10.1002/gps.70015